AstraZeneca | Business Post

AstraZeneca CEO says pharma giant chose Ireland over UK because of tax rates and green energy

Pascal Soriot said drugmaker initially wanted to make a $360 million investment in the UK but that the country’s tax rate was “discouraging”

Cost of AstraZeneca’s next-gen Dublin project may top €600m

Manufacturing facility likely to be much larger than initially planned

Matt Cooper: We can’t defer to Nphet as we did to the Church

No one disputes the sincerity or diligence of our public health officials, and the ugly online abuse of individuals is wrong, but we must be allowed to question their decisions

Analysis: Can we end the pandemic?

The possibility for more infectious and deadly variants appears endless – it will take a number of measures and innovations to subdue Covid-19 in future

Out of office: Your essential round-up of the latest business news

Analysis: Vaccine rollout keeps up to speed despite changes

With first doses for the over-65s and at-risk groups almost completed, new guidelines on vaccines should not greatly disrupt the programme

Glynn rules out offering choice of vaccines despite concerns over AstraZeneca

Deputy chief medical officer says maintaining high level of public confidence in vaccine rollout is crucial

Irish people under 30 should not be given AstraZeneca vaccine, epidemiologist says

When the incidence of Covid-19 is low, the potential harms to 20-29 year olds from the vaccine outweighed the benefits of preventing ICU admissions through vaccination, the MHRA found

Data check: The risk factor of AstraZeneca and what it means for vaccines rollout

New data has led to a change in policy across Europe on which age cohorts are safe to receive the AstraZeneca vaccine after reports emerged of rare blood clotting events. Will it affect Ireland’s vaccine rollout?

Colin Murphy: The good news is that our vaccine rollout is on course to meet targets

For all the gnashing of teeth over schools and vaccinations, the figures show that the vaccine delivery rate is set to surpass projections by a distance

AstraZeneca crisis proves short-lived

Some argue that Ireland’s prudence in suspending rollout over the blood clot issue will boost public confidence in vaccination. Others say it may cost lives

Interview: No rest for Ireland’s vaccine tsar

Brian MacCraith, chairman of the high-level taskforce on Covid-19 vaccination, has his work cut out in coordinating all bodies involved in the rollout

Susan O’Keeffe: Vaccine hubris has been undermined by reality

Tough talk between political leaders and states will not increase the supply of vaccines, a more collaborative approach is needed instead

Donnelly fears AstraZeneca may not deliver promised vaccines on time

Minister for Health admits concern after HSE misses last week’s target of 100,000 doses due to pharma company’s delay

Vaccination of community pharmacists to start this week

Move could result in vaccines being administered to the public at local pharmacies by the end of March

Early data shows that Britain’s vaccine programme is working

The over-80s benefited most with the weekly average for new cases falling more

Fewer GP surgeries will be able to offer vaccination to over-70s

Tánaiste says rollout to older people will be slower following recommendation that Pfizer and Moderna vaccines, rather than AstraZeneca, should be used for this group

Editorial: EU must rethink vaccine strategy after its misstep

By underestimating the logistics of a mass vaccination rollout, European leaders risk failing their citizens on this vital issue

Error upon error compounds the EU/AstraZeneca debacle

While AstraZeneca is interpreting its contractual responsibilities to the detriment of the EU, the European Commission is making matters worse by banning the export of vaccines from member states

Colin Murphy: The west’s vaccine greed could come back to haunt it

So-called ‘vaccine nationalism’ means richer countries have a surplus at the expense of poorer nations